Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1645 1647
This examiner grants 77% of resolved cases
Brian J. Gangle serves in Tech Center 1600 and Art Unit 1636. He has overseen 956 resolved cases, resulting in an allowance rate of 76.7 percent. This 76.7 percent allowance rate indicates a consistent level of success for applications on his docket. With 956 resolved cases, the data offers a clear view of his examination patterns.
The interview lift for Gangle is 14.7 percent. This 14.7 percent lift shows an improvement in allowance outcomes when an interview is conducted compared to cases without an interview. Practitioners should consider an interview as a helpful strategy, as the 14.7 percent lift suggests it is effective for overcoming rejections. This data point highlights the value of direct engagement in Art Unit 1636.
The median time to allowance is 951 days. This 951 day duration represents the typical timeframe from filing to a patent grant. Applicants can use this 951 day median to set realistic expectations for their prosecution timeline. The combination of a 76.7 percent allowance rate and this median pendency defines the current prosecution environment for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18114092 | USES OF UROLITHINS | Final Rejection | Amazentis SA |
| 18008108 | ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USING SAME | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 19111208 | MICROORGANISM SIMULTANEOUSLY PRODUCING 1,3-PROPANEDIOL AND 3-HYDROXYPROPIONIC ACID, AND USE THEREOF | Non-Final OA | LG CHEM, LTD. |
| 18682052 | EXOPOLYSACCHARIDE PRODUCTION MICROORGANISMS AND USES THEREOF | Non-Final OA | BASF SE |
| 18913647 | Combination Method For Treating Or Preventing Childhood Atopic Disease | Non-Final OA | Johnson & Johnson Consumer Inc. |
| 18621962 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | Non-Final OA | Pfizer Inc. |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | Non-Final OA | Ipsen Biopharm Limited |
| 19029331 | MDR E. COLI IMMUNOGEN | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 18040402 | BACTERIAL COMPOSITIONS WITH ANTI-INFLAMMATORY ACTIVITY | Final Rejection | Universiteit Gent |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | Non-Final OA | City of Hope |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy